Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — 20th Bioshares Biotech Summit 2026
18 slides from Bcal Diagnostics's conference presentation, Aug 6, 2026
Slide 1: BCAL: The Early Detection Company
T14 | Session 3: Diagnostics Feature BCAL: The Early Detection Company Anne-Louise Arnett Chief Executive Officer (ASX: BDX) 6 th August 2026 BCAL Diagnostics | 20th Bioshares Biotech Summit 2026
Slide 2: Who is BCAL
Who is BCAL BCAL Diagnostics | 20th Bioshares Biotech Summit 2026
Slide 3: Experienced Leadership
Experienced Leadership. ASX Code BDX Share Price July 2026 $0.08 Shares on Issue 368M Market Capitalisation $28M Jayne Shaw Jonathan Trollip Dr. John Hurrell PhD Dr David Darling Mark McConnell Chair Independent Independent Non-Executive Director Non-Executive Director Cash at 30 June 2026 Non-execu
Slide 4: BCAL Diagnostics - transforming early cancer detection
BCAL Diagnostics - transforming early cancer detection Markets 200+BREASTEST plus tests sold since launch Australian leader Addressing significant unmet need in breast, pancreatic, BCAL is a biotechnology and ovarian cancer, with Australian patent granted for in company developing house lipidomic te
Slide 5: Question: What is a negative test worth?
Question: What is a negative test worth? For most of the people we test, the negative result is the one that changes their day. That is where we think the value is. BCAL Diagnostics | 20th Bioshares Biotech Summit 2026
Slide 6: Accuracy is necessary. It is not what makes a test commercial.
Accuracy is necessary. It is not what makes a test commercial. A diagnostic can be highly accurate. Once a test clears the accuracy bar, three further questions decide whether it is adopted, repeated and paid for. 01 02 03 What decision How often is that Who pays? does the result decision made Tests
Slide 7: A blood test is already trusted
A blood test is already trusted The PSA test for prostate cancer, is a good model, because most of its value is in the negative result. A normal result reassures An abnormal result investigates 9 women die each day A low PSA lets a man and his doctor step back from further ~21,000 new cases annually
Slide 8: Sensitivity & Specificity
Sensitivity & Specificity A diagnostic test is like a security door People with the condition go through People without are stopped – ruled out Question Everyday Clinical meaning Terminology Does it find almost everyone who has the Don’t miss it Sensitivity condition? 9 women die Does it correctly c
Slide 9: What is published today
What is published today BREASTEST plus Avantect® Pancreatic Avantect® Ovarian SENSITIVITY SENSITIVITY SENSITIVITY 9 women die each day 90% 82.6% 78.2%~21,000 new cases annually SPECIFICITY SPECIFICITY SPECIFICITY In validation* 97.5% 94.0% 613 Australian women with identified 259 cancers vs 1,186 co
Slide 10: The negative result travels. The positive result depends on who you test.
The negative result travels. The positive result depends on who you test. Avantect® Pancreatic Testing groups where the cancer is more common, a positive result gets stronger. The negative result was already reliable and stays reliable. The same holds for breast and ovarian tests. This is the case f
Slide 11: Our validation runs on our samples
Our validation runs on our samples BREASTEST plus Closer to real use Our own cohorts Australian, and current 9 women die each day ~21,000 Samples come from the patients new cases Testing on our annually own current We collect our own patient samples. We invest in the cohort and settings these tests
Slide 12: One platform, four potential rule out applications
One platform, four potential rule out applications BREASTEST plus Avantect® Pancreatic Avantect® Ovarian BREASTEST Monitor Available now Available now Available now IN DEVELOPMENT Who Who Who Who Individuals at elevated risk of Individuals at elevated risk of Women who have completed 9 women die eac
Slide 13: Evidence gets a test approved. Infrastructure gets it used.
Evidence gets a test approved. Infrastructure gets it used. Adoption is built on the referral, collection and reporting pathway, so that every test we validate enters a channel that already exists. GP / Specialist Telehealth Blood Draw & Laboratory GP / Specialist Results Report Referral Collection
Slide 14: Moving forward
Moving forward TODAY NEXT THEN Clinician referred, patient The health economic case Public and private funded reimbursement Our tests are ordered and paid for now, through the pathway. Revenue accrues Rule out positioning is built on what a test avoids: unnecessary imaging, unnecessary 9 women die e
Slide 15: BCAL investment summary
BCAL investment summary Early cancer Large & growing Scalable access Commercial and Leadership and detection portfolio global markets platform clinical catalysts funding in place Blood-based tests Addressing National referral BREASTESTplus 2 Experienced across breast, significant unmet infrastructur
Slide 16: Looking ahead
Looking ahead Transitioned to a broader early cancer detection platform with national infrastructure and referral pathway established and funding secured for FY2027 Increase sales and referral volumes of Avantect® pancreatic and ovarian. Advance BREASTEST Monitor development and soft launch of Clear
Slide 17: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by BCAL Diagnostics The forward-looking statements are based on information available to BCAL Not An Offer Ltd ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change and the This Presentati
Slide 18: Thank you.
Information portal about early cancer earlydetection.com.au detection. Access telehealth appointments with medical professionals. Thank you. Pancreatic cancer 7.2% CAGR For further Information Anne-Louise Arnett Jayne Shaw Chief Executive Officer Chair Aarnett@bcaldiagnostics.com Jshaw@bcaldiagnosti
BCAL Diagnostics — 20th Bioshares Biotech Summit 2026 on 6ix